Landscape of prognostic signatures and immunogenomics of the AXL/GAS6 axis in renal cell carcinoma.

ABSTRACT:

Background

Cabozantinib is an oral tyrosine kinase inhibitor in renal cell carcinoma (RCC), whose targets include oncogenic AXL and unique ligand GAS6. Critical gaps in basic knowledge need to be addressed to devise an exclusive biomarker and candidate when targeting the AXL/GAS6 axis.

Methods

To clarify the effects of the AXL/GAS6 axis on RCC, we herein performed a large-scale immunogenomic analysis and single-cell counts including various metastatic organs and histological subtypes of RCC. We further applied genome-wide mutation analyses and methylation arrays.

Results

Varying patterns of AXL and GAS6 expression were observed throughout primary RCC tumours and metastases. Scoring individual AXL/GAS6 levels in the tumour centre and invasive margin, namely, the AXL/GA

SUBMITTER: Hakozaki K 

PROVIDER: S-EPMC8608819 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature